Navigation Links
First Evidence that Adipose Stem Cell-Based Critical Limb Ischemia Treatment is Safe & Effective is published in Circulation Journal by Lead Investigator Dr. Han Cheol Lee of Pusan National University
Date:9/4/2012

SEOUL, South Korea, Sept. 4, 2012 /PRNewswire/ -- Korean researchers, reporting the results of a major study in the Circulation Journal, found that the transplantation adipose (fat) derived stem cells resulted in the regeneration of blood vessels in patients who were otherwise expecting to receive limb amputations due to damaged arteries and lack of blood circulation.

Researchers at Pusan National University, led by Dr. Han Cheol Lee, describe how patients with critical limb ischemia (hereafter, CLI, example of which include Buerger's Disease and diabetic foot ulcers) were injected with adipose tissue-derived mesenchymal stem cell manufactured by RNL BIO.

As a result of the remarkable adipose stem cell process of RNL BIO, researchers found that immediate new blood vessel generation was identified. (The title of article is "Safety and Effect of Adipose Tissue-Derived Stem Cell Implantation in Patients With Critical Limb Ischemia")

CLI results from lack of circulation due to small artery damage and subsequent tissue necrosis. Patients with severe CLI often face limb amputation. Buerger's Disease, or diabetic foot ulcer, are of the same kind. Risk factors are diabetic mellitus, hypertension, high cholesterol and smoking. There is no known cure to date.

Currently percutaneous transluminal angioplasty or PTA may treat 60-70% of patients with CLI, but it doesn't work with those who suffer from Buerger's Disease. Working under approval to conduct compassionate use research of stem cell to treat CLI by intra-muscular injection of adipose tissue derived stem cells in December, 2008 (KFDA IND approval # 1273), the researchers in this study enrolled 15 subjects: 12 with Buerger's Disease, and 3 with Diabetic foot ulcers. 300 million stem cells were injected into each patient's leg.  No complications were observed, even six months after injection.

Only five patients, as they all had expected, required minor amputation during follow-up, and all amputation sites healed completely. At 6 months, significant improvement was noted in pain and in claudication walking distance. Digital subtraction angiography before and 6 months after ATMSC implantation showed formation of numerous vascular collateral networks across affected arteries.

Dr. Jeong-Chan Ra, President of RNL Stem Cell Technology Institute, said, "This new therapy through adipose tissue derived mesenchymal stem cell is expected to offer new hope for patients with CLI, hope that had been difficult to find before."


'/>"/>
SOURCE RNL Stem Cell Technology Institute
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. ESTEVE Announces the Publication of Comprehensive Phase I Data for a Novel Oral, First-in-class New Chemical Entity (NCE),E-52862, a Sigma-1 Receptor Antagonist (S1RA) Being Developed for Pain
2. Colbufalos Obtains First Success With Sexed Semen In Buffalo Breeding Industry
3. Texas Medical Center, the largest concentration of medical research, educational and healthcare organizations in the world, announces the first Houston Stem Cell Summit to highlight the latest stem cell research and commercialization efforts
4. Researchers pioneer worlds first HIV/AIDS nanomedicines
5. Bode Technology Offers First Rapid DNA Service Delivering a DNA Profile from Evidentiary Samples in Under 90 Minutes
6. Debiopharm Announces First Patient Enrolled in Phase III Study for the Rare Disease Central Precocious Puberty
7. China Cord Blood Corporation Reports Financial Results for the First Quarter of Fiscal 2013
8. China Cord Blood Corporation to Report First Quarter of Fiscal 2013 Financial Results
9. China Biologic Reports Financial Results for the Second Quarter and First Half of 2012
10. K-V Pharmaceutical "First Day" Motions Approved by U.S. Bankruptcy Court
11. Gevo Doesnt Infringe Butamaxs 017 Patent; Gevo was First to Invent Enzyme in 017 Patent; Gevo has Advanced Beyond That and Now Uses Different Enzymes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... UTAH. (PRWEB) , ... May 25, 2016 , ... WEDI, ... healthcare information exchange, today announced that Charles W. Stellar has been named by the ... interim CEO since January 2016. As an executive leader with more than 35 years ...
(Date:5/24/2016)... ... , ... Last week, Callan Capital, an integrated wealth management firm specializing in ... San Diego Life Science event at the Estancia La Jolla Resort and Spa. , ... speakers Dr. Rich Heyman, former CEO of Aragon and Seragon, and Faheem Hasnain, former ...
(Date:5/23/2016)... , May 23, 2016 Oxitec CEO ... th at 10:15 a.m. ET before the United States ... genetically engineered mosquitos can play in controlling the spread of ... the Zika virus.      (Logo: http://photos.prnewswire.com/prnh/20150630/227348 ... mosquito with a self-limiting gene. Trials in Brazil ...
(Date:5/20/2016)... ... May 20, 2016 , ... The leading Regenerative Veterinary ... most experienced veterinary clients have treated over 100 of their own patients with the ... provide the highest level of care for their patients. , The veterinarians are ...
Breaking Biology Technology:
(Date:3/14/2016)... 2016 NXTD ) ("NXT-ID" or the ... announces the airing of a new series of commercials on ... March 21 st .  The commercials will air on Bloomberg ... on the Street show. --> NXTD ) ("NXT-ID" ... commerce market, announces the airing of a new series of ...
(Date:3/11/2016)... 11, 2016 http://www.apimages.com ) - --> ... is available at AP Images ( http://www.apimages.com ) - ... used to produce the new refugee identity cards. DERMALOG will be ... CeBIT in Hanover next week.   --> ... be used to produce the new refugee identity cards. DERMALOG will ...
(Date:3/10/2016)... 2016 --> ... "Identity and Access Management Market by Component (Provisioning, Directory ... by Organization Size, by Deployment, by Vertical, and by ... The market is estimated to grow from USD 7.20 ... at a Compound Annual Growth Rate (CAGR) of 12.2% ...
Breaking Biology News(10 mins):